Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nanjing Legend Biotech
Biotech
ASH: Survival data on J&J's BCMA cell therapy keep on growing
After a median follow-up of 22 months, the cell therapy is yet to hit the median PFS or OS, suggesting it has an edge over Bristol Myers’ Abecma.
Nick Paul Taylor
Dec 12, 2021 4:30pm
FDA delays Legend, Janssen-partnered CAR-T cilta-cel
Nov 2, 2021 4:34am
Regenerative medicine nears banner year: report
Aug 18, 2021 9:00am
Johnson & Johnson culls $1.6B argenx blood cancer drug collab
Jun 7, 2021 4:14am
J&J's anti-BCMA CAR-T pads its case ahead of BMS showdown
Jun 1, 2021 8:30am
Legend Biotech, J&J finish off rolling submission for CAR-T
Apr 5, 2021 7:20am
